CLINICAL_TRIALS
trial_result
· 2019-09-26
Clinical Trial Update: Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]
Summary
Phase 1 study of ADCT-402 in relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL) was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ADC Therapeutics S.A. | Conditions: Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2019-09-26